[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352229-105":59,"doc-detail-352229-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","design-of-prodrugs-with-reactive-oxygen-species-as-activators-and-their-application-in-tumor-therapy","Design of prodrugs with reactive oxygen species as activators and their application in tumor therapy","","Major challenges lie in the precise management of malignant neoplasms, since conventional chemotherapy often suffers from poor targeting and substantial toxicity with frequent side effects. Cancer cells show markedly higher reactive oxygen species (ROS) levels than healthy tissues, enabling ROS-responsive prodrugs. This review summarizes recent advances in ROS-responsive small-molecule prodrugs and nanodelivery systems, detailing design principles across seven activation mechanisms. By integrating ROS responsiveness with tumor microenvironment specificity, the approaches achieve controlled drug release, reduced toxic effects, and synergistic therapy while supporting theranostic imaging for real-time monitoring, highlighting promise for clinical translation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/design-of-prodrugs-with-reactive-oxygen-species-as-activators-and-their-application-in-tumor-therapy/352229/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/design-of-prodrugs-with-reactive-oxygen-species-as-activators-and-their-application-in-tumor-therapy/352229.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are ROS-responsive prodrugs considered promising for tumor therapy?","Question",{"text":112,"@type":113},"Because ROS levels are observably elevated in cancer cells compared with healthy tissues, enabling prodrugs to be activated preferentially in tumor environments and improving targeting while reducing toxicity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What therapeutic benefits do ROS-responsive systems aim to deliver?",{"text":117,"@type":113},"They target controlled, precise drug release, significantly reduce toxic side effects, and can produce synergistic effects combining chemotherapy, immunotherapy, and photodynamic therapy.",{"name":119,"@type":110,"acceptedAnswer":120},"How do the reviewed systems incorporate tumor microenvironment specificity?",{"text":121,"@type":113},"They use TME as a natural trigger signal to reduce off-target activation by exploiting differences between tumor and normal tissues, such as ROS, RNS, thiol levels, viscosity, pH, and polarity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352229,1790218714,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Theranostics 2026, Vol. 16, Issue 3 1295  \nIvyspring  \nInternational Publisher  \nTheranostics  \n2026; 16(3): 1295-1327. doi: 10.7150/thno.121977  \nReview  \nDesign of prodrugs with reactive oxygen species as activators and their application in tumor therapy  \nJiaqi Xing1,\\#, Wenjuan Lu1,\\#, Yubing Zhang1, Chen Yang1, Jikai Yang1, Jing Shi2,􀀍, Yanfeng Wang1,􀀍  \n1. State Key Laboratory of Advanced Drug Delivery and Release Systems, Key Laboratory for Biotechnology Drugs of National Health Commission, Key Laboratory of Rare and Rare Diseases in Shandong Province, School of Pharmacy (Institute of Pharmacy) of Shandong First Medical University, Jinan, Shandong 250117, China.  \n2. Department of Pharmacy (Shandong Key Traditional Chinese Medical Discipline of Clinical Chinese Pharmacy), Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.  \n\\# These authors contributed equally to this work.  \n􀀍 Corresponding author: Y. F. Wang and Jing Shi, Email: [wangyanfeng@sdfmu.edu.cn](wangyanfeng@sdfmu.edu.cn).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2025.07.18; Accepted: 2025.10.10; Published: 2026.01.01  \nAbstract  \nMajor challenges lie in the precise management (encompassing diagnosis and treatment) of malignant neoplasms. Traditional chemotherapy faces restrictions in clinical use because of its ineffective targeting and significant toxicity, along with side effects. Notably, the ROS levels are observably elevated in cancer cells compared to healthy tissues, which presents a distinct opportunity for the creation of prodrugs that respond to ROS. This article systematically reviewed the research progress on ROS-responsive small molecule prodrugs and nanodelivery systems (including polymer/inorganic nanoparticles and hydrogels) over the past five years and elaborated in detail on the design principles based on seven key activation mechanisms. By combining ROS responsiveness with TME specificity, these systems have achieved precise controlled drug release, significantly reduced toxic and side effects, and demonstrated multiple synergistic effects of chemotherapy, immunotherapy, and photodynamic therapy. Additionally, some systems integrate theranostic and imaging functions, allowing real-time observation of the drug release. Subsequently, the latest progress in the field from molecular design to preclinical research was summarized, and the promise of ROS-responsive systems for clinical applications was emphasized. It directs the creation of prodrugs that are highly specific and supports the advancement of multi-responsive theranostic platforms, thereby paving the way for improved precision in the diagnosis and treatment of tumors.  \nKeywords: ROS, prodrugs, nanoparticles, tumor treatment  \n1. Introduction  \nA crucial obstacle in global public health is the growing importance of early detection and management of malignant tumors [1] . By the year 2025, it is forecasted that there will be 2 million newly diagnosed cases of cancer, with cancer-related deaths reaching 600,000 . In 2022, the survival rate increased by 34% compared to 1991, but it still adds up to a huge burden. Currently, traditional methods for treating cancer mainly consist of surgery, chemotherapy, radiotherapy, and immunotherapy; however, each of these treatments has notable limitations [2,3] . Due to the lack of accurate identification of tumor boundaries, surgical resection often faces a dilemma [4]: incomplete resection or excessive resection. The former may lead to tumor metastasis or recurrence,  \nwhile the latter tends to impair the normal physiological function of tissues and organs. Although systemic chemothera","cbCaitoJ5oBt3wgP","https://ap.wps.com/l/cbCaitoJ5oBt3wgP","pdf",13405182,33,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"Why are ROS-responsive prodrugs considered promising for tumor therapy?\",\"answer\":\"Because ROS levels are observably elevated in cancer cells compared with healthy tissues, enabling prodrugs to be activated preferentially in tumor environments and improving targeting while reducing toxicity.\"},{\"question\":\"What therapeutic benefits do ROS-responsive systems aim to deliver?\",\"answer\":\"They target controlled, precise drug release, significantly reduce toxic side effects, and can produce synergistic effects combining chemotherapy, immunotherapy, and photodynamic therapy.\"},{\"question\":\"How do the reviewed systems incorporate tumor microenvironment specificity?\",\"answer\":\"They use TME as a natural trigger signal to reduce off-target activation by exploiting differences between tumor and normal tissues, such as ROS, RNS, thiol levels, viscosity, pH, and polarity.\"}]","Design of prodrugs with reactive oxygen species as activators and their application in tumor therapy | PDF",1790098433,83,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55d04a5062f38270fd7506458175499b.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1cefb1691e65ff8e7b77bc5c5344f608.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d841e3c4fafa11947275736a548efff.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97d65595a60c49a5f888844ba8b6b756.webp",980,1268]